ATTAX 2

Phase II study of cetuximab (Erbitux™) plus weekly docetaxel chemotherapy in docetaxel refractory patients with EGFR positive advanced oesophago-gastric cancer.

Share

Trial Status

Completed

Cancer Type

Oesophageal Cancer

Aim

Most cases of oesophageal and gastric cancer are locally advanced or metastatic at presentation. Chemotherapy prolongs survival and improves quality of life in such patients, but standard chemotherapy for this disease has not been defined.

Summary

ATTAX 2 is an optional extension study for patients who have participated in the ATTAX study (AG0603) (all of whom receive docetaxel) and who have progressed either during or within six months of chemotherapy. The primary objective is to evaluate the response rate of cetuximab plus docetaxel in patients with docetaxel refractory advanced oesophago-gastric cancer. Secondary objectives include assessment of cetuximab plus docetaxel toxicity, progression free and overall survival, and improvements in symptom control.

Trial Status

Completed

Cancer Type

Oesophageal Cancer

Publication Reference

Tebbutt NC, Parry MM, Zannino D, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, Mellor D, Dobrovic A, Gebski VJ, on behalf of the Australasian Gastro-Intestinal Trials Group (AGITG). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. British Journal of Cancer 2013; 108(4): 771–774.

Conference Presentation Reference

  1. Tebbutt NC, Sourjina T, Strickland AH, Van Hazel G, Pavlakis N, Ganju V, Murone C, MacGregor D, Gebski V, Cummins M. ATTAX2—docetaxel plus cetuximab as second-line treatment for docetaxel refractory oesophago-gastric cancer: final results of a multi-center phase II trial by the AGITG. Gastrointestinal Cancers Symposium; 25–27 Jan 2008; Orlando. Abstract 87.
  2. Tebbutt NC, Sourjina T, Strickland AH, Van Hazel G, Pavlakis N, Ganju V, Murone C, MacGregor D, Gebski V, Cummins M. ATTAX2—docetaxel plus cetuximab as second-line treatment for docetaxel refractory oesophago-gastric cancer: final results of a multi-center phase II trial by the AGITG. 44th Annual Meeting of the American Society of Clinical Oncology; 30 May–3 Jun 2008; Chicago. Journal of Clinical Oncology 2008; 26 (May 20). Abstract 15554.

Aim

Most cases of oesophageal and gastric cancer are locally advanced or metastatic at presentation. Chemotherapy prolongs survival and improves quality of life in such patients, but standard chemotherapy for this disease has not been defined.

Summary

ATTAX 2 is an optional extension study for patients who have participated in the ATTAX study (AG0603) (all of whom receive docetaxel) and who have progressed either during or within six months of chemotherapy. The primary objective is to evaluate the response rate of cetuximab plus docetaxel in patients with docetaxel refractory advanced oesophago-gastric cancer. Secondary objectives include assessment of cetuximab plus docetaxel toxicity, progression free and overall survival, and improvements in symptom control.

Principal Investigator

Dr Niall Tebbutt, Medical Oncologist, Austin Health VIC

Funding

Alphapharm Pty Limited (Australia)